art_6__para_1__point_b__point_ii__text_2
the characteristics of and knowledge about the investigational medicinal products and the auxiliary medicinal products; the characteristics of the intervention compared to normal clinical practice; the safety measures, including provisions for risk minimisation measures, monitoring, safety reporting, and the safety plan; the risk to subject health posed by the medical condition for which the investigational medicinal product is being investigated;
← art_6__para_1__point_b__point_ii__text_1 · All articles · (c) →
Source: EUR-Lex (Cellar) · retrieved 2026-11-06 · Text as adopted (Official Journal); later amendments are not incorporated in this text.